U.S. stock market update: Vor BioPharma up 9.02%

U.S. Stock Market Midday Update Vor BioPharma, up 9.02%, with increased trading volume. Based on recent key news: On August 18, Vor Bio announced the grant of inducement stock options and restricted stock units under Nasdaq listing rule 5635(c)(4) to incentivize new employees. This news boosted market confidence, leading to a 9.02% increase in stock price. On August 18, Vor Bio released a press release detailing the grants of the aforementioned stock options and restricted stock units, further enhancing investor confidence. On August 18, Vor Bio's board compensation committee approved these grants during the period from August 4 to August 18, demonstrating the company's proactive measures to attract and retain talent, driving the stock price up. Stocks with High Trading Volume in the Industry AbbVie, up 2.30%, with increased trading volume. Based on recent important news: On August 19, AbbVie completed its acquisition of Capstan Therapeutics, with a transaction value of up to $2.1 billion, driving the stock price up 2.3%. On August 18, AbbVie's high dividend yield attracted long-term investors, enhancing market confidence. On August 17, although analysts maintained a moderate buy rating on AbbVie, its high dividend and growth potential were still viewed positively. Viking Therapeutics, up 5.28%, with a trading volume of $199 million. Based on recent key news: On August 19, Viking Therapeutics announced that its VK2735 achieved an average weight loss of 12.2% over 13 weeks, reaching both primary and secondary endpoints, leading to a 5.28% increase in stock price. On August 19, analysts expected VK2735's weight loss effect to be between 10% and 15%, and the actual results met expectations, prompting a positive market reaction. On August 20, analysts believed the market's reaction to VK2735 was excessive, with a minimum target price of $29, indicating a 20% upside potential for the stock price. Gilead Sciences, up 1.67%, with a trading volume of $117 million. Based on recent important news: On August 15, Gilead Sciences' Chief Financial Officer Andrew D. Dickinson sold 2,500 shares of the company's common stock for a total of $296,325. This move may raise market concerns about insider confidence in the company, leading to stock price volatility. On August 19, analysts rated Gilead Sciences as a moderate buy but believed that five other stocks offered better investment value, which could affect investor confidence in Gilead. On August 20, overall market trading warmed up, with a booming stock market benefiting economic activity and investment sentiment, potentially driving Gilead Sciences' stock price up Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen rose 1.38%, with a market capitalization of $161.4 billion. Based on recent important news: On August 18, market analysis showed that although Amgen was rated as a hold, it was not included in the five stocks recommended by analysts, indicating a cautious attitude towards its future performance, yet the stock price still rose by 1.38%. On August 17, Amgen was not listed among the five stocks recommended by analysts; nevertheless, the market still recognized its hold rating relatively highly. On August 20, the overall market was active, with capital inflows driving the stock market up, and Amgen benefited from the improvement in overall market sentiment